Wealthfront Advisers
IBRX icon

Wealthfront Advisers’s ImmunityBio IBRX Stock Holding History

Wealthfront Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Sell
11,528
-4,476
-28% -$33.9K ﹤0.01% 1094
2026
Q1 		$123K Buy
+16,004
New +$110K ﹤0.01% 1046
2025
Q4 		– Sell
-11,249
Closed -$27.7K – 1063
2025
Q3 		$27.7K Buy
+11,249
New +$29K ﹤0.01% 1005

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wealthfront Advisers's IBRX Position: Q2 2026 in Review

Wealthfront Advisers reduced its ImmunityBio (IBRX) stake by 28% in Q2 2026, selling an estimated $33.9K and leaving 11,528 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Wealthfront Advisers first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $123K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Wealthfront Advisers held 11,528 shares of ImmunityBio worth $101K as of Q2 2026.
  • Wealthfront Advisers sold 4,476 ImmunityBio shares in Q2 2026, an estimated $33.9K.
  • ImmunityBio made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1094 holding.
  • Wealthfront Advisers first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
  • Wealthfront Advisers's ImmunityBio position peaked at $123K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.